Compound class:
Peptide
Comment: NAB739 is from a series of polymyxin B analogues, designed to address the need for new antibacterial compounds with activity against multidrug-resistant (MDR) Gram-negative bacteria [1].
|
|
References |
1. Vaara M, Fox J, Loidl G, Siikanen O, Apajalahti J, Hansen F, Frimodt-Møller N, Nagai J, Takano M, Vaara T. (2008)
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob Agents Chemother, 52 (9): 3229-36. [PMID:18591267] |
2. Vaara M, Sader HS, Rhomberg PR, Jones RN, Vaara T. (2013)
Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. J Antimicrob Chemother, 68 (3): 636-9. [PMID:23134658] |
3. Vaara M, Vaara T, Vingsbo Lundberg C. (2018)
Polymyxin derivatives NAB739 and NAB815 are more effective than polymyxin B in murine Escherichia coli pyelonephritis. J Antimicrob Chemother, 73 (2): 452-455. [PMID:29149329] |